Elanco Animal Health Incorporated (NYSE:ELAN – Get Free Report) CEO Jeffrey Simmons purchased 4,971 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The stock was bought at an average price of $20.09 per share, for a total transaction of $99,867.39. Following the transaction, the chief executive officer directly owned 171,971 shares in the company, valued at $3,454,897.39. This trade represents a 2.98% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Elanco Animal Health Stock Performance
ELAN stock traded down $0.16 during trading on Tuesday, hitting $19.78. The company had a trading volume of 7,919,678 shares, compared to its average volume of 5,317,265. The firm has a market cap of $9.88 billion, a PE ratio of -39.55, a price-to-earnings-growth ratio of 2.14 and a beta of 1.69. Elanco Animal Health Incorporated has a 1-year low of $12.40 and a 1-year high of $27.72. The firm has a 50-day moving average price of $23.23 and a 200-day moving average price of $23.33. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60.
Elanco Animal Health (NYSE:ELAN – Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.06. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The firm had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.28 billion. During the same quarter in the previous year, the firm posted $0.37 EPS. The firm’s revenue for the quarter was up 14.9% on a year-over-year basis. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, analysts expect that Elanco Animal Health Incorporated will post 1.1 earnings per share for the current year.
Institutional Investors Weigh In On Elanco Animal Health
Analysts Set New Price Targets
Several research firms have issued reports on ELAN. KeyCorp boosted their target price on Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. UBS Group reiterated a “buy” rating on shares of Elanco Animal Health in a research report on Tuesday, March 10th. Morgan Stanley boosted their target price on Elanco Animal Health from $22.00 to $24.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 25th. Wall Street Zen upgraded Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Finally, Leerink Partners boosted their target price on Elanco Animal Health from $26.00 to $30.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 24th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $28.20.
View Our Latest Report on Elanco Animal Health
Elanco Animal Health Company Profile
Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.
Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.
Featured Articles
- Five stocks we like better than Elanco Animal Health
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
- Why Home Depot’s Sell-Off Could Become a Huge Opportunity
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
